New study demonstrates clinical utility of daxor's blood volume (bva-100®) diagnostic in heart failure outcomes

Daxor's bva technology shown to provide unique and individualized data for patient management oak ridge, tn, may 18, 2023 (globe newswire) -- daxor corporation (nasdaq: dxr), the global leader in blood volume measurement technology, today announces new data demonstrating the importance and clinical utility of daxor's bva-100 blood test in heart failure patients published in the european society of cardiology heart failure . the results of the study demonstrated daxor's blood volume analysis (bva) provides unique and individualized data that is critical for targeting heart failure therapy and is predictive of clinical outcomes.
DXR Ratings Summary
DXR Quant Ranking